SecBot SecBot
SECBOTREPLAY Home › Report › FBRX

FBRX · Forte Biosciences announced a $150 million public offering of 5.7…

Forte Biosciences, Inc. · 8-K filed Apr 9, 2026 at 06:14 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Apr 9, 2026 at 06:14 ET

Forte Biosciences announced a $150 million public offering of 5.7 million shares at $26.27 per share, with a 30-day option for underwriters to purchase an additional 856,490 shares. Concurrently, argenx BV made a strategic investment in the company. The proceeds will fund clinical development and general corporate purposes.

  • Forte Biosciences priced a public offering of 5,709,936 shares at $26.27 per share
  • Underwriters have a 30-day option to purchase up to an additional 856,490 shares
  • Gross proceeds expected to be approximately $150 million before underwriting discounts and commissions
  • Net proceeds estimated at $141 million ($162 million if full option exercised), to be used for clinical development and general corporate purposes

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access